NO20090450L - Tumorterapi med at anti-VEGF antistoff - Google Patents

Tumorterapi med at anti-VEGF antistoff

Info

Publication number
NO20090450L
NO20090450L NO20090450A NO20090450A NO20090450L NO 20090450 L NO20090450 L NO 20090450L NO 20090450 A NO20090450 A NO 20090450A NO 20090450 A NO20090450 A NO 20090450A NO 20090450 L NO20090450 L NO 20090450L
Authority
NO
Norway
Prior art keywords
vegf antibody
tumor therapy
present
her2
provides
Prior art date
Application number
NO20090450A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Friess
Werner Scheuer
Max Hasmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090450(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20090450L publication Critical patent/NO20090450L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO20090450A 2006-08-21 2009-01-29 Tumorterapi med at anti-VEGF antistoff NO20090450L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06017330 2006-08-21
PCT/EP2007/007276 WO2008022746A1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody

Publications (1)

Publication Number Publication Date
NO20090450L true NO20090450L (no) 2009-02-27

Family

ID=37607207

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090450A NO20090450L (no) 2006-08-21 2009-01-29 Tumorterapi med at anti-VEGF antistoff

Country Status (28)

Country Link
US (6) US20080050385A1 (pl)
EP (2) EP2441472B1 (pl)
JP (3) JP2010501498A (pl)
KR (1) KR101136763B1 (pl)
CN (1) CN101505792B (pl)
AR (1) AR062419A1 (pl)
AU (1) AU2007287794B2 (pl)
BR (1) BRPI0715829A2 (pl)
CA (1) CA2660681A1 (pl)
CL (1) CL2007002404A1 (pl)
CO (1) CO6150193A2 (pl)
CR (1) CR10590A (pl)
DK (1) DK2056874T3 (pl)
ES (2) ES2392630T3 (pl)
IL (2) IL196810A0 (pl)
MA (1) MA30654B1 (pl)
MX (1) MX2009001715A (pl)
MY (1) MY150756A (pl)
NO (1) NO20090450L (pl)
NZ (1) NZ574580A (pl)
PE (1) PE20080911A1 (pl)
PL (1) PL2056874T3 (pl)
RU (1) RU2528884C2 (pl)
SG (1) SG174090A1 (pl)
SI (1) SI2056874T1 (pl)
TW (2) TW200825106A (pl)
WO (1) WO2008022746A1 (pl)
ZA (1) ZA200901200B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1282443E (pt) * 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060121044A1 (en) * 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
BRPI0715829A2 (pt) * 2006-08-21 2013-07-23 Hoffmann La Roche terapia de tumor com um anticorpo anti-vegf
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech, Inc Predição de resposta a um inibidor de her
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US9714294B2 (en) 2010-05-27 2017-07-25 Genmab A/S Monoclonal antibodies against HER2 epitope
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
WO2012010546A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
PL2606070T3 (pl) * 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
WO2013083499A1 (en) * 2011-12-05 2013-06-13 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TW202140776A (zh) 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CN117752782A (zh) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
EP4208167A4 (en) * 2020-09-04 2024-11-13 The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Combination compositions and methods for treating cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0666868B2 (en) 1992-10-28 2006-06-14 Genentech, Inc. Use of anti-VEGF antibodies for the treatment of cancer
JPH11512750A (ja) 1996-06-27 1999-11-02 ファイザー インク． ２―（２―オキソ―エチリデン）―イミダゾリジン―４―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法
CA2269204C (en) 1996-10-18 2012-01-24 Genentech, Inc. Anti-erbb2 antibodies
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN101665536B (zh) 1997-04-07 2013-07-03 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
CA2341739C (en) 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
AP2001002079A0 (en) 1998-08-27 2001-03-31 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
ATE297916T1 (de) 1999-02-11 2005-07-15 Pfizer Prod Inc Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
DK1187632T3 (da) 1999-05-14 2009-04-06 Genentech Inc Behandling med anti-ErbB2-antistoffer
CN100381172C (zh) 1999-06-25 2008-04-16 吉尼泰克公司 使用抗-ErbB2抗体治疗前列腺癌
RU2270029C2 (ru) 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK1106612T3 (da) 1999-11-30 2004-05-17 Pfizer Prod Inc Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2466279A1 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20060036086A1 (en) 2002-03-12 2006-02-16 Jain Rakesh K Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
CA2481515C (en) 2002-04-10 2013-10-01 Genentech, Inc. Anti-her2 antibody variants
WO2005000090A2 (en) 2003-05-30 2005-01-06 Medi-Screw, Inc. Medical implant systems
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
EP1664115A2 (en) 2003-08-01 2006-06-07 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
AU2005282700A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101252306B1 (ko) * 2004-10-04 2013-04-08 제넨테크, 인크. 간세포 성장 인자 활성화제의 조정제
CN104436190A (zh) * 2005-06-08 2015-03-25 达纳-法伯癌症研究院公司 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
BRPI0715829A2 (pt) * 2006-08-21 2013-07-23 Hoffmann La Roche terapia de tumor com um anticorpo anti-vegf
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Also Published As

Publication number Publication date
MX2009001715A (es) 2009-02-25
ZA200901200B (en) 2013-08-28
ES2392630T3 (es) 2012-12-12
RU2009110102A (ru) 2010-09-27
US20100285010A1 (en) 2010-11-11
ES2546066T3 (es) 2015-09-18
WO2008022746A1 (en) 2008-02-28
JP2013163687A (ja) 2013-08-22
JP2015214582A (ja) 2015-12-03
US20130183292A1 (en) 2013-07-18
KR101136763B1 (ko) 2012-04-24
JP2010501498A (ja) 2010-01-21
TW201107346A (en) 2011-03-01
PE20080911A1 (es) 2008-08-15
US20080050385A1 (en) 2008-02-28
US20180251536A1 (en) 2018-09-06
US20150239969A1 (en) 2015-08-27
AU2007287794B2 (en) 2013-03-28
CL2007002404A1 (es) 2008-04-18
CN101505792A (zh) 2009-08-12
AU2007287794A1 (en) 2008-02-28
NZ574580A (en) 2011-12-22
CR10590A (es) 2009-03-20
EP2056874A1 (en) 2009-05-13
AR062419A1 (es) 2008-11-05
EP2441472A1 (en) 2012-04-18
CA2660681A1 (en) 2008-02-28
TW200825106A (en) 2008-06-16
BRPI0715829A2 (pt) 2013-07-23
SI2056874T1 (sl) 2012-12-31
KR20090032136A (ko) 2009-03-31
CN101505792B (zh) 2012-10-03
HK1134441A1 (en) 2010-04-30
DK2056874T3 (da) 2012-10-15
PL2056874T3 (pl) 2013-02-28
IL238045A0 (en) 2015-05-31
US20110223159A1 (en) 2011-09-15
SG174090A1 (en) 2011-09-29
MA30654B1 (fr) 2009-08-03
CO6150193A2 (es) 2010-04-20
IL196810A0 (en) 2011-08-01
EP2056874B1 (en) 2012-09-19
EP2441472B1 (en) 2015-06-10
MY150756A (en) 2014-02-28
RU2528884C2 (ru) 2014-09-20

Similar Documents

Publication Publication Date Title
NO20090450L (no) Tumorterapi med at anti-VEGF antistoff
NO20084546L (no) Diagnostikk og behandlinger for tumorer
CY1121813T1 (el) Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
LTPA2020536I1 (lt) Nauji anti-CD38 antikūnai, skirti vėžio gydymui
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
BRPI0513666A (pt) anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição
ATE461220T1 (de) Anti-egfr-antikörper
WO2007135546A3 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
IL185754A0 (en) Novel anti-plgf antibody
CY1114050T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
NO20082683L (no) Neuroendokrin tumorbehandling
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
NO20062885L (no) Terapeufiske anti-IGFR1-antistoffkombinasjoner
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
NZ595225A (en) Use of tnf inhibitor for treatment of erosive polyarthritis
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
PH12022552741A1 (en) Anti-ox40 antibody and uses thereof
WO2008054598A8 (en) Panel of biomarkers for prediction of fti efficacy
BRPI0512040A (pt) composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina
CL2011000911A1 (es) Composicion que comprende uno o mas antigenos, un solo dominio variable de inmunoglobulina antiproteina dc-sign y un vehiculo; metodo de elaboracion; y uso para el tratamiento de un tumor.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application